Press release BoxID: 173829 (Roche Diagnostics Deutschland GmbH)
  • Roche Diagnostics Deutschland GmbH
  • Sandhofer Str. 116
  • 68305 Mannheim
  • Contact person
  • Burkhard Ziebolz
  • +49 (8856) 60-4830

Roche NimbleGen ENCODE Arrays: The Most Sensitive Platform for ChIP-chip Experiments

(PresseBox) (Madison, ) Findings from the first ever systematic comparison of tiling microarray platforms showed the Roche NimbleGen ChIP-chip arrays for ENCODE (ENCyclopedia Of DNA Elements) studies to be the most sensitive platform detecting genome-wide, protein-DNA interactions. This study revealed that microarrays employing longer oligonucleotide probes (50mers) are the most sensitive at detecting very low enrichment in simulated ChIP-chip experiments.

As shown in the recently published, first objective analysis of tiling array platforms, DNA amplification procedures, and signal detection algorithms in a simulated ChIP-chip experiment by Johnson et al in Genome Research1, the NimbleGen ChIP-chip ENCODE arrays are the most sensitive platform at lower levels of enrichment. Predetermined DNA sequences were used to imitate chromatin immunoprecipitation experiments. The DNA sequences were not disclosed to the participating researchers in order to prevent a biased evaluation of each tiling array platform.

In the study, mixtures of human genomic DNA and predetermined "spike-in" DNA were hybridized to four tiling array platforms by eight independent groups. Blind to the number of spike-ins, their locations, and the range of concentrations, each group made predictions of the spike-in locations. Each array platform had unique performance characteristics that varied with tiling resolution and the number of determinations, which have implications for cost versus detection power.

A critical aspect in any microarray ChIP-chip experiment is the sensitivity of detection of low-fold enrichment. The unbiased analysis reported in this paper demonstrated that NimbleGen ChIP-chip ENCODE long oligonucleotide arrays are the most sensitive at detecting ultra low enrichment (1.25- to 2-fold) at a false discovery rate of 5%.

"We have been very pleased with the high sensitivity and reproducibility of NimbleGen Arrays," said Peggy Farnham, Ph.D., professor of pharmacology and associate director of genomics at the University of California-Davis. Dr. Farnham is a leading scientist in epigenetic research. "The high sensitivity has been especially critical for our studies of site-specific factors that are present at modest levels in human cells and tissues."

ChIP-chip arrays allow the identification of binding sites of DNA-binding proteins in a very efficient and scalable way. Currently the most popular platforms for performing ChIP-chip experiments are commercial oligonucleotide-based tiling microarrays. The NimbleGen ChIP-chip ENCODE microarray of Roche, designed in conjunction with the National Human Genome Research Institute (NHGRI)-funded ENCODE Project Consortium, contains more than 385,000 unique 50mer probes selected from 30 megabases of human sequence data. These probes are tiled, or spaced apart, every 38 bases, thus creating a 12-base overlap between probes, which is important for high-resolution mapping of binding sites. NimbleGen ENCODE array design of Roche is part of a larger program at the company to provide researchers with cutting-edge tools to investigate protein-DNA interactions on a genome scale using ChIP-chip analysis.

Roche NimbleGen offers both custom arrays as well as an extensive suite of catalog promoter and whole-genome tiling ChIP-chip arrays for many organisms. In addition, the company recently launched high-definition 2.1 million probe (HD2) ChIP-chip arrays for higher resolution analysis. The NimbleGen platform is widely accepted as the platform of choice for ChIP-chip experiments, with the number of peer-reviewed ChIP-chip publications on the NimbleGen platform totalling over 75, far exceeding that of all other ChIP-chip products on the market.

Roche NimbleGen is a leading innovator, manufacturer, and supplier of a proprietary suite of DNA microarrays, consumables, instruments, and services. Roche NimbleGen uniquely produces high-density arrays of long oligo probes that provide greater information content and higher data quality necessary for studying the full diversity of genomic and epigenomic variation. The improved performance is made possible by Roche NimbleGen proprietary Maskless Array Synthesis (MAS) technology, which uses digital light processing and rapid, high-yield photochemistry to synthesize long oligo, high-density DNA microarrays with extreme flexibility. For more information about Roche NimbleGen, please visit the company's website at

(1) Johnson DS et al: Systematic evaluation of variability in ChIP-chip experiments using predefined DNA targets. Genome Research; 18(3): 393-403. 2008.

Roche Diagnostics Deutschland GmbH

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders and diseases of the central nervous system. In 2007 sales by the Pharmaceuticals Division totaled 36.8 billion Swiss francs, and the Diagnostics Division posted sales of 9.3 billion francs. Roche has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai, and invested over 8 billion Swiss francs in R&D in 2007. Worldwide, the Group employs about 80,000 people. Additional information is available on the Internet at

LIGHTCYCLER and REALTIME READY are trademarks of Roche.